Elsevier

Neuroscience Letters

Volume 456, Issue 3, 12 June 2009, Pages 107-111
Neuroscience Letters

Review
Stem cell-based cell replacement strategies for the central nervous system

https://doi.org/10.1016/j.neulet.2008.04.106Get rights and content

Abstract

During human development, cells of the blastocyst inner cell mass proliferate and give rise to each cell in the human body. It is that potential which focuses intense interest on these stem cells as a substrate for cell-based regenerative medicine. An increased understanding of the interrelation of processes that govern the formation of various cell types will allow for the directed differentiation of stem cells into specified cells or tissues that can ameliorate the effects of disease or damage. Perhaps the most difficult cells and tissues to derive for use in cell replacement strategies are the diverse neurons, glia and complex networks of the central nervous system (CNS). Here we present emerging perspectives on the development of neuronal and glial cells from stem cells for clinical application to CNS diseases and injury.

References (49)

  • K. Takahashi et al.

    Induction of pluripotent stem cells from adult human fibroblasts by defined factors

    Cell

    (2007)
  • N.C. Bambakidis et al.

    Sonic hedgehog-induced neural precursor proliferation after adult rodent spinal cord injury

    Journal of Neurosurgery

    (2003)
  • T. Ben-Hur et al.

    Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis

    Glia

    (2003)
  • D. Bottai et al.

    Neural stem cells in the adult nervous system

    Journal of Hematotherapy & Stem Cell Research

    (2003)
  • O. Brustle et al.

    Embryonic stem cell-derived glial precursors: a source of myelinating transplants

    Science (New York, NY)

    (1999)
  • M.A. Caldwell et al.

    Growth factors regulate the survival and fate of cells derived from human neurospheres

    Nature Biotechnology

    (2001)
  • C. Cerdan et al.

    Complement targeting of nonhuman sialic acid does not mediate cell death of human embryonic stem cells

    Nature Medicine

    (2006)
  • F. Cloutier et al.

    Transplantation of human embryonic stem cell-derived oligodendrocyte progenitors into rat spinal cord injuries does not cause harm

    Regenerative Medicine

    (2006)
  • R.J. Colello et al.

    The role of oligodendrocytes and myelin on axon maturation in the developing rat retinofugal pathway

    Journal of Neuroscience

    (1994)
  • M. Drukker et al.

    Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells

    Stem Cells (Dayton, Ohio)

    (2006)
  • C.R. Freed et al.

    Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year

    Archives of Neurology

    (1990)
  • T.B. Freeman et al.

    Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease

    Annals of Neurology

    (1995)
  • F.H. Gage et al.

    Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain

    Proceedings of the National Academy of Sciences of the United States of America

    (1995)
  • P.J. Horner et al.

    Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord

    Journal of Neuroscience

    (2000)
  • Cited by (44)

    • Neural regeneration therapies for Alzheimer's and Parkinson's disease-related disorders

      2020, Biochimica et Biophysica Acta - Molecular Basis of Disease
    • Mesenchymal stem cell therapies in brain disease

      2019, Seminars in Cell and Developmental Biology
      Citation Excerpt :

      Whether these MSCs are fully cleared from the body or are so widely diffused that they cannot be tracked is unclear; regardless, this would limit the number of MSCs that could have the potential to reach the brain. As an alternative, localized injection of MSCs has been employed, such as intranasal application as a non-invasive method to deliver SC directly into the central nervous system (CNS) [43]. These localized delivery methods, such as intranasal delivery, appear to minimize the issue of lung entrapment and yield higher homing of injected MSCs to the brain [101,102].

    • Transplantation of Human Umbilical Cord Blood Mononuclear Cells Attenuated Ischemic Injury in MCAO Rats via Inhibition of NF-κB and NLRP3 Inflammasome

      2018, Neuroscience
      Citation Excerpt :

      Correspondingly, as shown in Fig. 6(B, C and D), the contents of VEGF, Ang-1 and Tie-2 were elevated in cbMNCs-treated group, indicating the more potent angiogenesis of cbMNCs. Transplantation of stem cells may be considered as an alternative treatment for the neurodegenerative diseases (Pluchino et al., 2005; Sharp and Keirstead, 2009; Erceg et al., 2010; Bigini et al., 2011; Reimers et al., 2012). One of the advantages of the cbMNCs is that the cells can prevent the graft-versus-host disease (Parmar et al., 2014).

    • Mesenchymal stem cells as therapeutic agents and potential targeted gene delivery vehicle for brain diseases

      2012, Journal of Controlled Release
      Citation Excerpt :

      Besides the neurotrophic factors, MSCs can produce the extracellular matrix molecules that can support neural cell attachment, growth and axonal extension [19]. Several studies have proved that MSCs can be induced to express neural markers in vitro [20,21], while after stem cells migrating in the brain, some new neurons in the adult human hippocampus have been found [18,22,23]. There is no precise definition of mechanisms of stem cell‐based therapy for brain diseases yet; however, as beneficial effects have been demonstrated, details inside cell therapy need further investigation.

    View all citing articles on Scopus
    View full text